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Edited by Giulio Superti-FurgaAbstract Protein kinase C delta (PKCd) is a Ser/Thr kinase
which regulates numerous cellular processes, including prolifera-
tion, diﬀerentiation, migration and apoptosis. Here, we demon-
strate that PKCd undergoes in vitro autophosphorylation at
three sites within its V3 region (S299, S302, S304), each of
which is unique to this PKC isoform and evolutionarily con-
served. We demonstrate that S299 and S304 can be phosphory-
lated in mammalian cells following phorbol ester stimulation and
that S299-phosphorylated PKCd is localised to both the plasma
and nuclear membranes. These data indicate that PKCd is phos-
phorylated upon activation and that phospho-S299 represents a
useful marker of the activated enzyme.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Protein kinase C delta (PKCd) is a diacylglycerol/phorbol es-
ter dependent, but calcium insensitive, Ser/Thr kinase of the
PKC superfamily [1,2]. PKCd is ubiquitously expressed and
has been implicated in the control of cell proliferation [3], dif-
ferentiation [4], migration [5] and apoptosis [6,7]. The charac-
terisation of PKCd null mice has revealed non-redundant
functions for this enzyme in the immune system [8–10], smooth
muscle cell homeostasis [11] and ischemic preconditioning [12].
Signiﬁcantly, a growing body of work indicates that PKCd acts
as a tumour suppressor, presumably through its well-docu-
mented growth inhibitory and/or pro-apoptotic activities (re-
viewed in [13]).
In light of the wide physiological signiﬁcance of PKCd, an
important objective is to investigate the relationship between
its dysregulation and disease. Since PKCd is allosterically con-
trolled, it may be more meaningful to test for changes in its
activity than expression level in this context [14]. Previously,
a PKCa autophosphorylation site was exploited as a marker
of its activity, revealing PKCa activation in 11/23 breast tu-
mour specimens [15]. Since S643 represents an important PKCd
autophosphorylation site [16], it might be considered as anAbbreviations: BIM1, bisindolylmaleimide I; PKC, protein kinase C;
PMA, phorbol 12-myristate 13-acetate; RCC, renal cell carcinoma
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doi:10.1016/j.febslet.2007.06.035appropriate marker for similar analyses. However, this site is
relatively resistant to dephosphorylation and remains occupied
even when PKCd releases its activator, diacylglycerol, and
adopts a ‘closed’ conformation [17]. Thus, S643 phosphoryla-
tion is unlikely to represent a robust indicator of acute activa-
tion status. In the present study, we sought to identify inducible
PKCd autophosphorylation sites, which might prove amenable
to monitoring PKCd activity in disease samples.
2. Materials and methods
2.1. Materials
All reagents were purchased from Sigma–Aldrich unless otherwise
indicated.
2.2. In vitro kinase assays
Kinase assays were performed using 500 ng human PKCd (Calbio-
chem) in the following buﬀer: 20 mM Tris, pH 7.5, 5 mM MgCl2,
1 lg/ ll phosphatidylserine (Lipid Products), 0.2% Triton X-100,
1 ng/ ll phorbol 12-myristate 13-acetate (PMA), 50 lM ATP, 5 lCi
[c-32P]-ATP (Amersham). Reactions were incubated for 0–120 min at
30 C with shaking, resolved by SDS–PAGE, Coomassie stained and
analysed using the Storm 860 Phosphorimaging System (Molecular
Dynamics).
2.3. Mass spectrometry and Edman degradation
In vitro phosphorylated PKCd was digested in-gel with trypsin (Pro-
mega) for 4 h at 37 C and peptides separated by reverse-phase HPLC.
MALDI-TOF was performed using an Applied Biosystems 4700 Pro-
teomics Analyzer. Edman degradation was carried out using an ABI
Procise Sequencer and sequelon acrylamine membranes.
2.4. Phosphospeciﬁc antibodies
Phosphopeptides were prepared (CR-UK Peptide Synthesis Labora-
tory), coupled to Keyhole Limpet Hemocyanin using glutaraldehyde
and immunised in triplicate (Harlan Sera-Lab): phosphoS299, N-
TQRApSRRSD; phosphoS304, N-SRRSDpSASSE (a blocking
dephosphopeptide was also synthesised for each site). At least one spe-
ciﬁc rabbit antiserum was obtained for each site: phosphoS299 (PPA-
535); phosphoS304 (PPA-514).
2.5. Constructs
PKCd (NM_006254) was cloned into the pEGFP-C1 vector (EcoRI/
BamHI) using the following PCR primers: 5 0-atattagaattcaa-
tggcgccgttcctgcgcatcgc-30 and 5 0-taatatggatcctcaatcttccaggaggtgctcg-
3 0. PKCd mutants were generated by site directed mutagenesis, using
mutagenic primer pairs: S299A, 5 0-gccgcccggagatcagactcagcctcctca-
gagcctgttggg-3 0 and 5 0-ggctgagtctgatctccgggcggctctctgggtgacttgg-30;
S304A, 5 0-cggagatcagacgcagcctcctcagag-3 0 and 5 0-ctctgaggaggctgcgtct-
gatctccg-30. All constructs were sequence veriﬁed.
2.6. Cell culture, transfection and treatment
COS7 and HeLa cells (CR-UK) were maintained in DMEM/10%
FCS (PAA Laboratories) + penicillin/streptomycin at 37 C, in a
humidiﬁed atmosphere containing 5% CO2. RCC4-VA cells wereblished by Elsevier B.V. All rights reserved.
3378 J. Durgan et al. / FEBS Letters 581 (2007) 3377–3381cultured as described [18]. Serum starvation was performed using
DMEM/0.25% FBS overnight. Transfections were carried out with
Lipofectamine 2000 (Invitrogen). PMA and the following inhibitors
were all reconstituted in DMSO and used as described in the ﬁgure leg-
ends: Staurosporine, Go¨6983, BIM1, Go¨6976 (Calbiochem).
2.7. SDS–PAGE and Western blotting
Cells were washed in PBS, scraped into 2· LDS sample buﬀer (Invit-
rogen)/0.2 M DTT, boiled for 5 min and sonicated. SDS–PAGE was
performed using the NuPAGE system (Invitrogen) with either 4–12%
Bis–Tris (GFP-PKCd), or 3–8% Tris-acetate gels (endogenous PKCd).
Western blotting was carried out as described [19], using rabbit anti-
phosphoS299/phosphoS304 (1:1000 + 1 lg/ml blocking dephospho-
peptide), mouse anti-GFP (3E1, CR-UK; 1:1000) or rabbit anti-PKCd
(C17, Santa Cruz; 1:5000). The Western blots shown are representative
of data obtained from three separate experiments.
2.8. Confocal microscopy
Cells were seeded on acid-washed, glass coverslips and transfected/
treated as indicated. They were ﬁxed using 4% paraformaldehyde/
PBS for 10 min, quenched with 50 mM NH4Cl/PBS for 10 min, andA
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Fig. 1. PKCd in vitro autophosphorylation and phosphopeptide mapping. (A
SDS–PAGE and stained using Coomassie; [c-32P]-incorporation was analyse
was digested with trypsin, fractionated by reverse-phase HPLC and liquid s
spectrometry; residue numbers correspond to human PKCd (NP_006245).
(PSD) of the phosphopeptide decreases this by 98 Da. (D) Fraction 33 (Sa
individual amino acids were liquid scintillation counted. The corresponding
major phosphorylated sites are indicated with arrows. (E) Fraction 35 (Samppermeablised and blocked in 0.2% Triton X-100/2% BSA/TBS for
10 min. Cells were incubated with anti-PKCd phosphoS299 (1:100,
2% BSA/TBS + 1 lg/ml blocking dephosphopeptide) for 1 h, washed
in TBS and stained with Alexa Fluor 568 goat anti-rabbit secondary
antibody for 1 h (Molecular Probes; 1:500, 2% BSA/TBS). Coverslips
were washed in TBS, then in water and mounted onto glass slides using
Mowiol 4-88 (Calbiochem). Images were acquired using a confocal, la-
ser scanning microscope [18]. Each image represents a single 1.0 lm
‘Z’ section and is representative of data obtained from three separate
experiments.3. Results
3.1. Identiﬁcation of three novel, in vitro PKCd
autophosphorylation sites
Phosphopeptide mapping was performed on in vitro-auto-
phosphorylated PKCd (Fig. 1A) to identify the phosphory-
lated residue(s); the data presented here were collated from
two separate experiments (Samples 1 and 2). Phosphorylated32
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) PKCd in vitro kinase assays were incubated for 0–30 min, resolved by
d by phosphorimaging. (B) In vitro phosphorylated PKCd (Sample 1)
cintillation counted. (C) Fraction 34 (Sample 1) was analysed by mass
Phosphorylation increases peptide mass by 80 Da, post-source decay
mple 1) was subjected to Edman degradation, fractions representing
peptide sequence identiﬁed by mass spectrometry is shown, and the
le 2) was analysed by mass spectrometry and (F) Edman degradation.
Fig. 2. PMA-induced stimulation of PKCd phosphorylation in mam-
malian cells. (A) COS7 cells were transfected with GFP-PKCd, GFP-
PKCd S299A or (B) GFP-PKCd S304A, incubated for 24 h and then
treated /+ 400 nM PMA for 40 min. Total cell extracts were prepared
and analysed by Western blotting. (C) RCC4-VA cells were serum
starved, pre-treated /+ 1 lM Staurosporine (STS), 6 lM Go¨6983,
2 lM BIM1 or 1 lMGo¨6976 for 15 min and then stimulated /+
400 nM PMA for 15 min; inhibitor speciﬁcities are shown [14]. Total
cell extracts were prepared and analysed by Western blotting.
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HPLC and fractions were counted to locate 32P-labelled phos-
phopeptides (Fig. 1B and data not shown). Selected, 32P-la-
belled fractions were analysed by both mass spectrometry
and Edman degradation. As shown in Fig. 1C, a peptide was
detected from Fraction 33 (Sample 1) corresponding to PKCd
residues 298–318, plus two phosphate moieties. Edman degra-
dation revealed that the labelled residues are located at posi-
tions 2 and 5, and thereby identiﬁed S299 and S302 as
phosphorylation sites (Fig. 1D). From Fraction 35 (Sample
2), two peptides were identiﬁed with masses corresponding to
PKCd residues 301–318 and 302–318, plus one phosphate
group (Fig. 1E); Edman cycle sequencing revealed S304 as
an additional phosphorylation site (Fig. 1F). We obtained evi-
dence for the autophosphorylation of further PKCd residues,
however, no others were distinguished unequivocally. In sum-
mary, these data identify three novel PKCd in vitro autophos-
phorylation sites, S299, S302 and S304, of which at least two,
S299 and S302, can be phosphorylated simultaneously.
3.2. Cellular phosphorylation of PKCd at S299 and S304
The cellular phosphorylation of PKCd was investigated
using phosphospeciﬁc antisera. GFP-PKCd was ectopically ex-
pressed in COS7 cells, in the presence or absence of PMA, a
cPKC/nPKC activating phorbol ester. We observed a degree
of basal S299 phosphorylation under these conditions, which
was substantially increased following PMA treatment, indicat-
ing that both constitutive and induced signals can elicit PKCd
activation. Since no signiﬁcant immunoreaction was evident
using the non-phosphorylatable GFP-PKCd S299A mutant,
the antibody speciﬁcity was conﬁrmed. Using a similar ap-
proach, we showed that PKCd S304 is also phosphorylated
in response to PMA (Fig. 2B). However, a weak, inducible sig-
nal was detected using the GFP-PKCd S304A mutant, suggest-
ing recognition of an additional distinct, PMA-stimulated
PKCd phosphorylation site. The cross-reactivity of the S304
antiserum, although weak, precluded its use in immunolocali-
sation studies (see below).
We veriﬁed that endogenous PKCd is S299-phosphorylated
in response to PMA in renal cell carcinoma (RCC) VA cells
(Fig. 2C), which we have previously characterised with respect
to PKCd-VHL interactions and PKCd phosphorylation status
[18]. Furthermore, by employing a panel of inhibitors with dif-
ferent, but overlapping, speciﬁcities, we investigated the mech-
anism of PMA-induced PKCd phosphorylation. As indicated
in Fig. 2C, the inhibition of PMA-induced S299 phosphoryla-
tion detected in the presence of staurosporine, Go¨6983 and
BIM1 is consistent with autocatalysis; however, we cannot ex-
clude the possibility that other PKC isoforms, with the same
pharmacological proﬁles as PKCd, may also play a role. Addi-
tionally, since partial inhibition was observed in the presence
of Go¨6976 (80 ± 14% relative to controls; n = 3), cPKC activ-
ity may also contribute, in a limited fashion, to S299 phos-
phorylation under these conditions.
3.3. Localisation of phosphoS299-PKCd
Immunoﬂuorescence was performed to examine the subcel-
lular localisation of S299-phosphorylated PKCd (Fig. 3). In
unstimulated COS7 and HeLa cells, both GFP-PKCd and
GFP-PKCd S299A are uniformly distributed, with some accu-
mulation in a perinuclear compartment (nuclear localisation of
GFP-PKCd was observed in some cells and is thus not uniqueto the S299A mutant; data not shown); a weak phosphoS299
signal can be detected under these conditions. In response to
PMA, COS7 cells undergo a dramatic morphological change
and both PKCd and PKCd S299A are translocated to the plas-
ma and the nuclear membranes. The anti-phosphoS299 signal
is clearly increased in cells expressing the wild type, but not
mutant protein, indicating that PKCd undergoes S299 phos-
phorylation upon its activation in both membrane compart-
ments. Similar results were observed in HeLa cells, except
that the translocation to, and phosphorylation at, the plasma
membrane is most pronounced at cell–cell contacts (Fig. 3).4. Discussion
In the present study we identify three novel PKCd in
vitro autophosphorylation sites: S299, S302 and S304. As
Fig. 3. Localisation of S299-phosphorylated GFP-PKCd in COS7 and HeLa Cells. (A) COS-7 or (B) HeLa cells were transfected with GFP-PKCd or
GFP-PKCd S299A, incubated for 24 h and treated ± 400 nM PMA for 40 min. The cells were ﬁxed and stained for anti-phosphoS299 PKCd. For
comparison, consistent laser settings were used to collect all images.
A
B
Fig. 4. Sequence conservation of novel PKCd phosphorylation sites
S299, S302 and S304. (A) PKCd is represented diagrammatically, with
novel phosphorylation sites S299, S302 and S304 highlighted and
conserved (C) and variable (V) domains shown. (B) PKCd sequence
alignments. Underlined text represents the C1a/b domains of S. pombe
pck2; the following symbols denote the degree of conservation: (*)
identical; (:) conservative; (.) semi-conservative; ( ) no conservation.
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region of the molecule and are conserved among diﬀerent
organisms, suggesting functional signiﬁcance. Equivalent sites
were not identiﬁed in lower organisms, however, their similar-
ity with the residues between the C1a/C1b domains of pck2
from Schizosaccharomyces pombe is noteworthy; autophos-
phorylation within the equivalent region has been observed
in PKCh [20] and PKCe (Durgan et al., manuscript in prepa-
ration). Signiﬁcantly, the sequence surrounding this cluster
of phosphorylation sites is unique to PKCd among mamma-
lian PKC superfamily members, indicating that they represent
isoform-speciﬁc modiﬁcations.
Using phosphospeciﬁc antibodies we have demonstrated
that both S299 and S304 can be phosphorylated in mammalian
cells in response to PMA, and interestingly, have localised
S299-phosphorylated PKCd to both the plasma and nuclear
membranes. However, it appears that S299 phosphorylation
is neither required for PKCd recruitment to, nor dissociation
from, these compartments, since wild type and mutant proteins
are similarly distributed. Further functional studies will be re-
quired to determine whether PKCd phosphorylation at S299,
S302 and/or S304, inﬂuences either substrate recruitment or in-
duced degradation/cleavage.
Using pharmacological inhibitors, we have shown that PKC
activity is required for the PMA-induced phosphorylation of
endogenous PKCd in RCC VA cells, consistent with our char-
acterisation of this residue as an in vitro autophosphorylation
site. Notably, S299 represents a highly optimal PKCd consen-
sus sequence, scoring within the top 5th percentile using a pre-
dictive database [21]. However, from our current data, we
cannot conclude deﬁnitively that, in the cell, S299 is phosphor-
ylated by PKCd alone, since modest inhibition was observed
with Go¨6976. It is likely that the broad and overlapping spec-
iﬁcities of PKC isoforms [22], alongside the fact that cPKCs
and nPKCs are co-recruited to the membrane in response to
PMA, leads to some limited, cPKC-mediated phosphorylation
of PKCd.These mechanistic issues have implications for the use of
‘autophosphorylation’ sites as markers of activated PKC. If
a site is not exclusively phosphorylated via autocatalysis, it
J. Durgan et al. / FEBS Letters 581 (2007) 3377–3381 3381does not represent a true marker of inherent activity. However,
if phosphorylation via any mechanism (auto- or trans-) occurs
speciﬁcally upon membrane recruitment and cofactor binding,
then, as an extractable marker of activation, it should prove
highly informative. Thus, the PKCd S299 phosphorylation site
described herein represents a marker with which to screen for
alterations in PKCd activity, and thus to deﬁne the contribu-
tion of this enzyme to cancer and other conditions, directly
from patient samples.
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